Hakutulokset - Margarida Alves de Mesquita

Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study Tekijä Brandon J. Essink, Craig Shapiro, Marie Grace Dawn Isidro, Paul Bradley, Antoinette Pragalos, Mark Bloch, Joel Santiaguel, Melchor Victor Frias, Spiros Miyakis, Margarida Alves de Mesquita, Stefano Berrè, Charlotte Servais, Natasha Waugh, Claudia Hoffmann, Emna Baba, Oliver Schönborn-Kellenberger, Olaf-Oliver Wolz, Sven D. Koch, Tapiwa Ganyani, Philippe Boutet, Philipp Mann, Stefan O. Mueller, Roshan Ramanathan, Martin Robert Gaudinski, Nicolas Vanhoutte

Connect to this object online.